What is Epigeneres?
Epigeneres is a prominent biotechnology firm dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines targeting serious medical conditions and the diseases associated with ageing. The company leverages cutting-edge genetic therapeutics and tissue generation technologies, aiming to address significant unmet medical needs and improve the lives of millions globally. A key innovation is Epigeneres' proprietary nano-particle based delivery mechanism, which substantially enhances the efficacy of active molecules and ensures electrolytic compatibility with gene proteins. This technological prowess positions Epigeneres among the world's leading biotech entities, with a robust pipeline that includes both nutraceutical molecules and promising prescription (Rx) drug candidates.
How much funding has Epigeneres raised?
Epigeneres has raised a total of $6M across 1 funding round:
Series B
$6M
Series B (2022): $6M with participation from LetsVenture Angel Fund, Moez Daya, and Kotak Investment Advisors
Key Investors in Epigeneres
LetsVenture Angel Fund
LetsVenture Angel Fund is an investment entity that typically backs early-stage companies, providing crucial seed capital and strategic guidance to foster growth and innovation.
Moez Daya
Moez Daya is an individual investor, likely contributing expertise and capital to promising ventures within the biotechnology or pharmaceutical sectors.
Kotak Investment Advisors
Kotak Investment Advisors is a financial services firm that provides investment management and advisory services, often participating in significant funding rounds for companies with strong growth potential.
What's next for Epigeneres?
The recent major strategic investment signals a pivotal growth phase for Epigeneres, likely enabling the company to accelerate its research and development pipeline, scale manufacturing capabilities, and expand its market reach. This capital infusion is expected to fuel the advancement of its novel drug candidates through clinical trials and towards commercialization. The company's focus on genetic therapeutics and tissue generation, coupled with its advanced delivery system, positions it for significant impact in addressing age-related diseases and other serious medical conditions. Future strategic partnerships and further funding rounds may be anticipated as Epigeneres continues to mature its innovative therapeutic platforms.
See full Epigeneres company page
